metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-2409 [-3048; -1769] /10000 80/409 vs. 158/362	-
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	167 [-366; 701] /10000 45/314 vs. 40/316	-
	relatlimab plus nivolumab vs. nivolumab alone	1	-	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	1217 [-2442; 4876] /10000 12/23 vs. 4/10	-1783 [-5280; 1715] /10000 12/23 vs. 7/10	-
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	-	-2590 [-4480; -700] /10000 30/72 vs. 25/37	-